Business Wire

CO-NEWMONT-CORPORATION

Share
Newmont and Project C.U.R.E. – Two Decades of Partnership Delivering Global Medical Support

Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) and Project C.U.R.E. announce a five-year agreement to deliver medical supplies and life-saving training for healthcare providers in developing countries and communities near Newmont mining operations. Under the agreement, Newmont commits to an annual contribution of $200,000 over the next five years, totaling $1 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208935869/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Newmont and Project C.U.R.E.’s partnership has created a positive economic ripple effect across 36 countries. (Graphic: Business Wire)

“Creating a positive impact on more than 10 million people globally, through our partnership with Project C.U.R.E. is something we are incredibly proud of,” said Suzy Retallack, Newmont’s Chief Safety and Sustainability Officer. “For nearly two decades, our partnership has helped deliver support to host communities near our operations and around the world. We look forward to continuing to leverage our combined global reach to make a strong impact where it is needed most.”

Since 2005, Newmont has partnered with Project C.U.R.E. to distribute more than $42 million worth of much-needed medical supplies and equipment through multiple sponsorship initiatives. Highlights of the partnership include:

  • Funding 108 shipping containers of medical equipment to 36 countries.
  • Impacting more than two million patients through Newmont’s support of the C.U.R.E. Cargo program.
  • Training more than 440 medical professionals, through the C.U.R.E. College program, in resource-limited environments to reduce neonatal and maternity morbidity and mortality.
  • Contributing $5 million to support humanitarian efforts relating to the ongoing war in Ukraine, providing direct support to Project C.U.R.E., the American Red Cross and International Medical Corps.
  • Delivering 164 C.U.R.E. kits – suitcase-sized, pre-packed kits of essential medical supplies – through Newmont employees to healthcare facilities in Ethiopia, Ghana, Indonesia, Mexico, Nicaragua, Peru and Suriname.

“We are proud of our partnership with the team at Newmont. For nearly two decades, we have worked together to save lives and strengthen the healthcare infrastructure for millions of people,” said Dr. Douglas Jackson, President and CEO of Project C.U.R.E. “In countries like Ghana and Suriname and now Mexico, Guatemala and others, we have established a figurative gold standard for corporate social responsibility and making our communities healthier, happier and more hopeful.”

Also, as part of Newmont’s partnership, employees around the world participate in myriad volunteer opportunities – logging hundreds of hours of time and service helping sort supplies at the Project C.U.R.E. warehouse, packing and unloading containers, and carrying medical kits to communities near Newmont operations.

About Project C.U.R.E.

Established in a garage in Evergreen, Colorado in 1987, Project C.U.R.E. has grown to be the world’s largest distributor of donated medical supplies and equipment to people living in developing countries. Since 2000, Project C.U.R.E. has delivered more than $1 billion of medical relief to save the lives of people facing poverty, disasters and violence. Project C.U.R.E. has worked in 138 countries, establishing an incredible footprint of medical relief around the world.

As a registered 501(c)(3), Project C.U.R.E.’s goal is to bridge the staggering health resource gaps in the developing world by empowering doctors and nurses with the tools they need—medical supplies and equipment—to treat disease, deliver vaccines, perform life-changing surgeries, and ensure safe childbirth. On average, Project C.U.R.E. delivers five forty-foot containers of donated medical relief each week.

About Newmont

Newmont is the world’s leading gold company and a producer of copper, zinc, lead, and silver. The company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in Africa, Australia, Latin America & Caribbean, North America, and Papua New Guinea. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social, and governance practices. Newmont is an industry leader in value creation, supported by robust safety standards, superior execution, and technical expertise. Founded in 1921, the company and has been publicly traded since 1925.

At Newmont, our purpose is to create value and improve lives through sustainable and responsible mining. To learn more about Newmont’s sustainability strategy and initiatives, go to www.newmont.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240208935869/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye